m 102.4

Drug Profile

m 102.4

Alternative Names: Antiviral monoclonal antibody - Profectus BioSciences; Hendra virus monoclonal antibody - Profectus BioSciences; m 102; m102.4 mAb; Nipah virus monoclonal antibody - Profectus BioSciences

Latest Information Update: 31 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Institute (USA); Profectus Biosciences; Uniformed Services University of the Health Sciences
  • Developer Profectus Biosciences
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Eph family receptor modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Nipah virus infections
  • No development reported Viral infections

Most Recent Events

  • 28 May 2018 No recent reports of development identified for phase-I development in Viral-infections(In volunteers) in Australia (IV, Infusion)
  • 24 May 2018 Preclinical development is ongoing in USA
  • 24 May 2018 The Coalition for Epidemic Preparedness Innovations, Profectus BioSciences and Emergent BioSolutions enter into a research and development agreement for Nipah virus vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top